BlueRipple Health

Guidelines

Each entry analyzes one clinical guideline or consensus statement behind cardiovascular care — what it recommends, why it matters, and how much weight it deserves. We rate every source for evidence strength and clinical significance.

32 analyses

2022 ACC Expert Consensus Decision Pathway on Nonstatin Therapies for LDL-C Lowering

ACC, 2022 · Consensus statement

85

ACC/AHA Guidelines for Exercise Testing

ACC/AHA, 1997 · Clinical practice guideline

80

2018 Guideline on the Management of Blood Cholesterol

AHA/ACC, 2018 · Clinical practice guideline

95

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

AHA/ACC, 2019 · Clinical practice guideline

95

2025 AHA/ACC Clinical Performance and Quality Measures for Chronic Coronary Disease

AHA/ACC, 2025 · Performance measures

92

ASNC Task Force on Women and Heart Disease: Perfusion Imaging in Women

ASNC Women Task Force, 2003 · Consensus statement

75

PET Myocardial Glucose Metabolism and Perfusion Imaging: Part 1 — Data Acquisition and Patient Preparation

Bacharach et al., 2003 · Clinical practice guideline

55

Lipoprotein Management in Patients with Cardiometabolic Risk

Brunzell et al., 2008 · Consensus statement

65

Apolipoprotein B and Cardiovascular Disease Risk: AACC Position Statement

Contois et al., 2009 · Position statement

85

Shared Decision-Making and Cardiovascular Health

Dennison Himmelfarb et al., 2023 · Scientific statement

80

Plant Sterols and Plant Stanols in the Management of Dyslipidaemia and Prevention of Cardiovascular Disease

EAS Consensus Panel, 2014 · Consensus statement

78

2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice

ESC CVD Prevention, 2016 · Clinical practice guideline

95

2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC/EAS, 2019 · Clinical practice guideline

95

Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease — EAS Consensus Statement

Ference et al., 2017 · Consensus statement

95

Crossing the Quality Chasm: A New Health System for the 21st Century

IOM, 2001 · Consensus report

85

A Focused Update to the 2019 NLA Scientific Statement on Lipoprotein(a) in Clinical Practice

Koschinsky et al., 2024 · Scientific statement update

88

Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis — EAS Consensus Statement

Kronenberg et al., 2022 · Consensus statement

85

Psychological Health, Well-Being, and the Mind–Heart–Body Connection

Levine et al., 2021 · Scientific statement

60

Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of ASCVD

Lloyd-Jones et al., 2018 · Special report

85

Life's Essential 8: Updating the AHA's Construct of Cardiovascular Health

Lloyd-Jones et al., 2022 · Presidential advisory

65

An Assessment by the Statin Muscle Safety Task Force: 2014 Update

NLA Muscle Safety Task Force, 2014 · Expert consensus statement

82

NLA Scientific Statement on Coronary Artery Calcium Scoring to Guide Preventive Strategies

NLA, 2021 · Scientific statement

88

Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults

NLA, 2024 · Expert clinical consensus

90

Lipoprotein(a) as a Cardiovascular Risk Factor: Current Status — EAS Consensus

Nordestgaard et al., 2010 · Consensus statement

88

Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice

Pearson et al., 2003 · Scientific statement

85

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for ASCVD

Reyes-Soffer et al., 2022 · Scientific statement

88

Clinical Indications for Coronary Artery Calcium Scoring in Asymptomatic Patients

SCCT CAC Consensus, 2017 · Expert consensus statement

88

CAC-DRS: Coronary Artery Calcium Data and Reporting System

SCCT CAC-DRS, 2018 · Expert consensus statement

85

PET Myocardial Perfusion and Glucose Metabolism Imaging: Part 2 — Interpretation and Reporting

Schelbert et al., 2003 · Practice guideline

70

Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: USPSTF Recommendation Statement

USPSTF, 2018 · Recommendation statement

85

2021 ACC Expert Consensus Decision Pathway on ASCVD Risk Reduction in Persistent Hypertriglyceridemia

Virani et al., 2021 · Consensus statement

78

Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations

Wilson et al., 2021 · Scientific statement

85